Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
Sponsor: Dizal Pharmaceuticals
Summary
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is patients with primary ITP who had failed to respond or relapsed after receiving at least one standard therapy. Participants who meet the inclusion criteria and do not meet the exclusion criteria will be randomized to different dose groups.
Official title: A Phase 2 Study to Evaluate the Efficacy and Safety of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-01-15
Completion Date
2027-12
Last Updated
2026-01-22
Healthy Volunteers
No
Conditions
Interventions
DZD8586 dose level 1
DZD8586 will be administered orally in a 28-day cycle.
DZD8586 dose level 2
DZD8586 will be administered orally in a 28-day cycle.
DZD8586 dose level 3
DZD8586 will be administered orally in a 28-day cycle.
Locations (1)
Qilu Hospital of Shandong University
Jinan, Shandong, China